Scientists working on a potential coronavirus vaccine have almost reached a breakthrough on an antibody treatment which could saves the lives of the elderly and vulnerable, it has been reported.
An injection of cloned antibodies which allows the body to counteract Covid-19 could prove hugely significant for those in the early stages of infection, according to British-Swedish pharmaceutical company AstraZeneca.
The company has already started to manufacture the Oxford University Covid-19 vaccine to ensure, if it does pass human trials, it can be made available in the autumn.
On Thursday, AstraZeneca signed a deal with the Coalition for Epidemic Preparedness Innovations (Cepi) to help manufacture 300 million globally accessible doses of the coronavirus vaccine candidate being developed by the Jenner Institute at the University of Oxford.
READ MORE: Coronavirus: global battle for control of Covid vaccine
One member of the coalition is the Serum Institute of India, which The Sunday Telegraph reports is considering other “parallel” partnerships with AstraZeneca that may lead to the antibody treatment being funded as a stand-alone treatment.
AstraZeneca’s chief executive Pascal Soriot told the newspaper that the treatment being developed is “a combination of two antibodies” in an injected dose “because by having both you reduce the chance of resistance developing to one antibody”.
Antibody therapy is more expensive than vaccine production, with Mr Soriot saying the former would be prioritised for the elderly and vulnerable “who may not be able to develop a good response to a vaccine”.
READ MORE: Vaccine could train body to fight coronavirus, say scientists
It comes as trials of the potential vaccine have started in Brazil, a new epicentre of the pandemic, to ensure the study can be properly tested as transmission rates fall in the UK.
The Jenner Institute and the Oxford Vaccine Group began development on a vaccine in January, using a virus taken from chimpanzees.
Coronavirus comment: Why we must start planning for a vaccine now
Meanwhile, UK-based vaccine manufacturer Seqirus announced it is working in partnership with parent company CSL, CEPI and the University of Queensland to help develop a candidate Covid-19 vaccine in Australia.
Its manufacturing base in Liverpool is producing an adjuvant, an agent which improves the immune response of a vaccine.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereLast Updated:
Report this comment Cancel